SEGMENTS (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the three months ended March 31, 2024 and 2023:

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Three Months Ended on March 31, 2024
Revenue	$	5,752,994		$	-		$	535		$	332,678		$	6,086,207
Cost of Sales		(4,533,660	)		-			(2,041	)		(122,666	)		(4,658,367	)
Gross Margin		1,219,334			-			(1,506	)		210,012			1,427,840
Operating Expenses		(361,696	)		(163,707	)		(826,961	)		(2,341,990	)		(3,694,354	)
Operating Income (Loss)		857,638			(163,707	)		(828,497	)		(2,131,977	)		(2,266,513	)
Other Income (Expense)		15,148			(3,491,466	)		(205,821	)		1,365,140			(5,047,279	)
Net Income (Loss) Before Income Tax		872,786			(3,655,173	)		(1,034,288	)		(3,497,117	)		(7,313,792	)

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Three Months Ended on March 31, 2023
Revenue	$	633,811		$	14,040		$	12,786		$	266,299		$	926,936
Cost of Sales		(602,340	)		(4,568	)		(14,367	)		(68,006	)		(689,281	)
Gross Margin		31,471			9,472			(1,581	)		198,293			237,655
Operating Expenses		(440,017	)		(139,903	)		(141,290	)		(1,606,175	)	$	(2,327,385	)
Operating Loss		(408,546	)		(130,431	)		(142,871	)		(1,407,882	)		(2,089,730	)
Other Income (Expense)		45			(1,061,068	)		319,635			(1,492,064	)	$	(2,233,452	)
Net Loss Before Income Tax		(408,501	)		(1,191,499	)		176,764			(2,899,946	)		(4,323,182	)
March 31, 2024
Cash and Restricted Cash	$	2,988,864		$	312,996		$	411,751		$	20,979,265		$	24,692,876
Total Assets		63,338,168			2,340,946			2,077,355			28,953,819			96,710,288
December 31, 2023
Cash and Restricted Cash	$	3,323,210		$	430,807		$	568,702		$	23,566,574		$	27,889,293
Total Assets		62,989,233			5,845,269			2,450,876			55,028,650			126,314,028